Coefficient of variation based multiplexed ELISA biomarker selection in HNPCC Syndrome Patients

October 6, 2021

Conference

Coefficient of variation based multiplexed ELISA biomarker selection in HNPCC Syndrome Patients

D. Pitlor, R. E. Brand, B. Dudley, E. Karlowski, A. Zyhowski, E. J. Metter, R. M. Brand, S. Uttam

Biomedical Engineering Society (BMES) 2021 Annual Meeting (Oct 6 - 9, 2021; Orlando, Florida). Abstract reu-007-3147, BMES 2021 Annual Meeting.

We present some preliminary results on a method to analyze assays such as multiplexed enzyme-linked immunosorbent (ELISA) assay to identify analytes whose expression are not meaningful and should be removed from further analysis.

More News

We have published a pilot study demonstrating the ability of nanoscale nuclear architecture mapping method to predict neoplastic progression in Barrett's esophagus patients

January 26, 2022

BMES 2021 Annual Meeting (Unsupervised segmentation of complex tissue using multiplexed imaging-derived a priori knowledge)

October 6, 2021

BMES 2021 Annual Meeting (Demonstration of ability of nanoscale nuclear architecture mapping to study chromatin alteration)

October 6, 2021

BMES 2021 Annual Meeting (Coefficient of variation based multiplexed ELISA biomarker selection in HNPCC Syndrome Patients)

October 6, 2021

United States Patent 11,105,686 B2 was granted to us

August 31, 2021

CTSI Biomedical Modeling Pilot Award

June 1, 2021

SPIE Photonics West 2021 (Nanoscale nuclear architecture mapping capturing chormatin reorganization in epithelial cells undergoing malignant transformation)

March 1, 2021

Collaborative work on developing pre-clinical ex vivo system using human colorectal tissue for drug testing in inflammatory bowel disease has been published

March 1, 2021